Health100 is designed as a cross-stakeholder digital destination, avoiding closed proprietary architectures to connect ...
In today’s Pharma Pulse, Antengene and UCB ink a $1.18 billion global deal for ATG-201 to target autoimmune diseases, while ...
Esperion Therapeutics has entered into a definitive agreement to acquire Corstasis Therapeutics, a privately held biopharmaceutical company. The acquisition focuses on the integration of Enbumyst™ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results